Telehealth ADHD Prescribing: What Psychiatrists Can Do in New York

If you’re a psychiatrist or PMHNP considering ADHD medication management via telehealth, you’re probably asking: Can I legally prescribe stimulants online? What are the rules in my state? And is this actually a viable practice model?

The short answer: Yes, psychiatrists can prescribe ADHD medications through telehealth — including Schedule II stimulants like Adderall and Ritalin — but the specifics depend on federal regulations, state laws, and your credential type. As of 2026, temporary federal flexibilities allow controlled substance prescribing without an initial in-person exam through the end of 2025, though the future remains uncertain.

Let’s break down exactly what psychiatrists and PMHNPs can do, the state-by-state differences that matter, and what this means for building a sustainable ADHD practice.

What Federal Law Says About Prescribing ADHD Medications via Telehealth

Here’s the regulatory reality: ADHD medications — primarily amphetamines (Adderall, Vyvanse) and methylphenidate (Ritalin, Concerta) — are Schedule II controlled substances. That classification subjects them to the Ryan Haight Act, which historically required at least one in-person medical evaluation before a provider could prescribe controlled substances via telemedicine.

During the COVID-19 pandemic, the DEA waived this in-person requirement. That waiver has been extended multiple times, most recently through December 31, 2025. This means that throughout 2024-2025, psychiatrists could initiate stimulant prescriptions for new ADHD patients entirely through video visits, provided they conducted appropriate clinical evaluations.

What happens in 2026? That’s the multi-billion dollar question. If Congress doesn’t pass permanent telehealth prescribing legislation or the DEA doesn’t finalize new rules, we could revert to requiring in-person exams for new controlled substance patients. The DEA has floated ideas about a ‘special registration’ for telemedicine providers, but nothing concrete has been implemented yet.

For practicing psychiatrists, this means: you can currently prescribe ADHD meds via telehealth, but stay alert to regulatory changes and have contingency plans (partnerships with local clinics for in-person exams, for example) if the rules shift mid-year.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist vs PMHNP Authority: The Critical Differences

The scope of practice gap between psychiatrists and psychiatric nurse practitioners becomes stark when it comes to ADHD prescribing — not because of clinical competency, but because of state-by-state legal restrictions.

Psychiatrists (MD/DO): Universal Authority

As a physician, you have full prescriptive authority in every state. No supervision required. No quantity limits. No special carve-outs. Your only constraints are:

• Valid DEA registration
• State medical license where the patient is located
• Compliance with controlled substance monitoring (PDMP checks)
• Standard of care requirements

This makes psychiatrists indispensable for telehealth platforms, especially those operating nationally or in restrictive states.

PMHNPs: State-by-State Maze

Nurse practitioners face a patchwork of regulations that can dramatically limit ADHD prescribing:

Full Practice Authority States (after experience requirements):

• New York: After 3,600 supervised hours (~2 years), PMHNPs can prescribe all controlled substances independently
• Illinois: After 4,000 hours + 250 hours additional training, full authority granted
• California: Transitioning to independence; experienced NPs (104 status) can prescribe after 3 years/4,600 hours

Restricted States with Significant Limitations:

• Texas: PMHNPs cannot prescribe Schedule II stimulants for outpatient ADHD under any circumstances (except hospitalized/hospice patients). Only physicians can write these prescriptions.
• Florida: Requires physician supervision; NPs limited to 7-day Schedule II supplies except psychiatric nurses working under a psychiatrist’s protocol (they can prescribe 30-day supplies)
• Pennsylvania: NPs can only prescribe 72 hours of Schedule II initially for new patients, then 30-day supplies with physician re-evaluation

The practical impact? In states like Texas, ADHD telehealth platforms need psychiatrists to handle stimulant prescribing. PMHNPs can manage therapy, coordinate care, and prescribe non-stimulants (atomoxetine, viloxazine, bupropion), but they hit a legal wall with Adderall.

State-Specific Rules That Actually Matter

Let’s cut through the generic advice and focus on what’s different in the states where ADHD care demand is highest:

Texas: Psychiatrists Are Essential

Texas explicitly prohibits NPs from prescribing Schedule II controlled substances in outpatient settings. Combined with one of the worst psychiatrist shortages in the nation (1 per ~9,000 residents), this creates massive demand.

What works: Collaborative models where psychiatrists handle medication while NPs or therapists provide counseling. But the psychiatrist is doing the prescribing, period. Texas requires video (not phone-only) for controlled substance prescribing and expects documentation equivalent to in-person care.

Market reality: Rural Texas has essentially zero psychiatric access. Telehealth is literally the only option for most counties. If you’re a Texas-licensed psychiatrist, you can build a full practice in months.

Florida: Telehealth-Friendly with Caveats

Florida’s law explicitly permits telehealth prescribing of Schedule II medications for psychiatric disorders — a specific carve-out that makes ADHD treatment legal and straightforward for both MDs and properly supervised PMHNPs.

The catch: PMHNPs need a psychiatrist collaborator and technically fall under the ‘psychiatric nurse’ designation (which exempts them from the normal 7-day Schedule II limit). This is workable, but it means psychiatric NPs can’t practice solo in Florida.

Market reality: Severe shortage (1:8,577 ratio), huge and growing population, many patients willing to pay out-of-pocket due to long wait times. The state actively supports telehealth infrastructure.

New York: NP Independence After Dues Are Paid

New York offers a clear pathway: 3,600 supervised hours, then full autonomy. Once independent, a PMHNP has the same prescribing authority as a psychiatrist for ADHD medications.

The requirements: Must complete collaboration period first. Mandatory e-prescribing. Must check state PDMP (I-STOP registry) before every controlled substance prescription — this is non-negotiable and audited.

Market reality: NYC has plenty of providers, but upstate and rural counties are underserved. Telehealth lets urban providers reach those areas. Strong insurance coverage and parity make this financially viable.

California: Mid-Transition

California is phasing in NP independence through the AB 890 framework. By 2026, many experienced PMHNPs have achieved ‘104’ status and can practice independently.

Current state: New NPs still need physician supervision (103 status) for their first 3-4 years. All NPs prescribing Schedule IIs must complete a specialized pharmacology course.

Market reality: Enormous population, tech-savvy patient base, high ADHD awareness especially in urban areas. Competitive but with persistent gaps in Central Valley and rural regions. Strong parity laws mean good reimbursement.

Pennsylvania: Collaboration Required, Initial Rx Limited

PA’s 72-hour initial prescription limit for NP-prescribed Schedule IIs creates workflow friction. Many practices have the physician write the first script, then the NP handles monthly refills (30-day limit).

Workaround: Close physician-NP coordination. The collaborating psychiatrist stays involved early in treatment.

Market reality: Decent supply in Philadelphia/Pittsburgh, shortages everywhere else. Telehealth fills gaps but the NP restrictions mean you need MDs on the team.

Illinois: Path to Independence

Similar to New York but requires more hours (4,000). Once FPA is granted, PMHNPs can prescribe all ADHD medications independently (the opioid consultation requirement doesn’t apply to stimulants).

Market reality: Chicago is saturated, downstate Illinois desperately needs providers. Strong Medicaid telehealth coverage makes this accessible to underserved populations.

The Real Economics: Patient Acquisition and Platform Value

Let’s address the elephant in the room: how do you actually build a patient panel for ADHD care without burning through marketing budgets?

The DIY Marketing Reality Check

Many providers starting out think: ‘I’ll just do my own marketing — SEO, Google Ads, a Psychology Today listing. How hard can it be?’

Here’s what that actually costs:

SEO: 6-12 months before you see meaningful patient flow. You’re looking at $2,000-4,000/month for content, technical optimization, and link building if you hire an agency. Most solo practitioners don’t have the expertise to do this effectively themselves.

Google Ads: Mental health keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. Factor in landing page optimization, ad testing, managing no-shows from cold leads, and your cost per actually seen patient is typically $200-400 or higher.

Directory Listings: Psychology Today charges monthly fees and you’re competing with hundreds of other providers on the same page. Zocdoc charges $35-100+ per booking plus monthly subscription fees. Your total monthly cost can easily hit $500-1,000 just for directory presence, with no guarantee of patient quality or volume.

Staff Time: Someone has to answer calls, qualify leads, handle scheduling, follow up with no-shows. That’s either your time (unpaid) or staff cost.

Failed Experiments: Most providers waste $3,000-5,000 testing marketing channels that don’t work for their specialty or geography before finding something effective.

Total Reality: Acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ when you account for ALL costs — and that’s after months of investment with no returns.

The Platform Alternative: Pay Only for Actual Patients

This is where the economic model shifts entirely. Platforms like Klarity use a pay-per-appointment structure — you pay a standard listing fee when a pre-qualified patient actually books with you.

Why this matters:

• Zero upfront marketing spend — no $5,000/month gamble on Google Ads
• No wasted clicks — every dollar goes toward an actual patient appointment
• Pre-qualified patients already matched to your specialty and availability
• Built-in infrastructure — telehealth platform, scheduling, billing support included (no separate $200-300/month platform fees)
• Predictable costs — you know exactly what you’re paying per new patient
• Scale at your pace — control your schedule, only pay when you see patients

The math: Instead of spending $3,000-5,000/month with uncertain results, you pay a per-appointment fee only when someone shows up. That’s guaranteed ROI vs gambling on marketing channels.

For psychiatrists especially, this is attractive because your time is the constraint — not patient demand. ADHD patients are actively seeking care. The question is: do you want to spend your time managing marketing campaigns, or seeing patients?

Clinical Workflows: Making Telehealth ADHD Care Actually Work

The regulatory stuff matters, but so does the practical ‘how do I actually do this safely and efficiently?’

Initial Evaluation

Comprehensive assessment via video:

• Full psychiatric history and DSM-5 ADHD diagnostic criteria
• Standardized rating scales (ASRS for adults, Vanderbilt/Conners for pediatric)
• Collateral information where appropriate (school reports, partner observations)
• Screen for comorbidities (anxiety, depression, substance use)
• Baseline vital signs (patients can self-report BP/HR or get them at pharmacy/PCP)

Documentation requirements:

• Verify patient identity and location (for licensure compliance)
• Document informed consent for telehealth and controlled substance risks
• PDMP check (required in most states before Schedule II prescribing)
• Justification for diagnosis and medication choice

Billing: Typically CPT 90792 (psychiatric diagnostic evaluation), reimbursed ~$188-202 by Medicare, often $200-300 by commercial insurers.

Ongoing Medication Management

Monthly follow-ups are standard for stimulant management (insurance often requires this frequency for controlled substances):

• 10-15 minute video visits
• Monitor efficacy, side effects, vital signs
• Adjust dose if needed
• PDMP re-check (at least every 90 days in most states)
• Address any concerns about diversion or misuse

Billing: CPT 99213 (15 min) or 99214 (25 min), reimbursed ~$89-95 (99213) or $125-136 (99214) by Medicare. Commercial payers typically equal or higher.

E-prescribing: All Schedule II prescriptions must be sent electronically through a DEA-compliant system (two-factor authentication required). Paper prescriptions are rarely accepted anymore.

Safeguards Against Misuse

Given the increased scrutiny on telehealth ADHD prescribing (after some high-profile cases of overprescribing), build these into your workflow:

• Urine drug screening if any red flags or history of substance misuse
• Treatment agreements outlining expectations, no early refills, one provider rule
• Careful documentation of continued medical necessity
• Red flag monitoring: multiple pharmacies, lost prescriptions, escalating doses without clinical justification
• Periodic in-person coordination with PCP or local provider if patient has complex medical issues

This isn’t just risk management — it’s demonstrating that virtual ADHD care meets the same standard as in-person treatment.

Reimbursement: The Financial Reality of Telehealth ADHD Care

One of the biggest provider concerns: ‘Will I actually get paid for virtual visits?’

Short answer: Yes, and probably just as well as in-person care.

Telehealth Parity is Now Standard

As of 2026, nearly 48 states have some form of telehealth payment parity for mental health services. Private insurers in most states are required to reimburse telehealth at the same rate as in-person visits.

Medicare: Extended telehealth coverage for mental health through at least 2024, with likely further extensions. Pays non-facility rates (full amount) for psychiatric telehealth. No difference between virtual and in-person reimbursement for medication management.

Medicaid: Most state Medicaid programs now cover telepsychiatry at parity. Rates are lower than Medicare (often ~$40-65 for a brief med check) but the volume can make up for it.

Commercial Insurance: Often pays equal to or better than Medicare. Many plans reimburse $120-150+ for a 15-minute med management visit (99213) and $160-200+ for 25-minute visits (99214).

Real Numbers for ADHD Medication Management

Initial evaluation (90792):

• Medicare: ~$188-202
• Commercial: $200-300
• Medicaid: $80-120 (varies widely by state)

Follow-up visits:

• 99213 (15 min): Medicare ~$89-95, Commercial ~$110-140, Medicaid ~$40-65
• 99214 (25 min): Medicare ~$125-136, Commercial ~$150-200, Medicaid ~$60-90

Psychiatrists earn more than other provider types for identical services in most insurance networks — your MD/DO license commands higher reimbursement rates. Some insurers pay NPs at 85% of physician rates, but psychiatrists typically bill at the full physician fee schedule.

The Math of a Full Schedule

If you’re doing medication management via telehealth:

• Four 15-minute appointments per hour (99213)
• At Medicare rates: 4 × $90 = $360/hour gross
• At commercial rates: 4 × $125 = $500/hour gross
• 8 patients/day, 4 days/week = 128 patients/month
• At blended rates (~$110 average per visit) = $14,000+/month gross revenue

With telehealth overhead being minimal (no office rent, minimal staff), your net income percentage is significantly higher than traditional practice.

Medication Shortages: The Current ADHD Prescribing Challenge

Let’s address the practical headache every ADHD provider deals with in 2024-2026: ongoing stimulant shortages.

Prescriptions for ADHD medications surged during the pandemic as adults sought help and telehealth made access easier. This increased demand combined with DEA manufacturing quotas created persistent shortages of Adderall, Vyvanse, and other stimulants.

What this means for your practice:

• Patients will come to you already frustrated from pharmacy to pharmacy rejections
• You’ll need to be flexible with alternatives (different formulations, non-stimulants)
• Good relationships with local pharmacies matter
• Clear communication about shortages prevents patient blame/frustration directed at you

Non-stimulant options you should be comfortable prescribing:

• Atomoxetine (Strattera)
• Viloxazine (Qelbree)
• Bupropion (off-label)
• Clonidine/guanfacine (especially for pediatric cases)

The providers who navigate shortages well — helping patients find alternatives or pharmacies with stock — build tremendous loyalty. This is a service differentiator in a crowded market.

Why ADHD Telehealth Makes Sense as a Practice Focus

Let’s be direct about the business case:

High Demand, Persistent Undersupply

• Adult ADHD diagnosis rates have surged — people who struggled for years finally seeking help
• Pediatric ADHD wait times in many areas are 6+ months
• Provider shortages (especially in TX, FL, rural areas) mean demand far exceeds supply
• Telehealth removes geographic barriers — you can see patients across your state(s)

Strong Economics

• Consistent patient flow once established (ADHD requires ongoing medication management)
• Short appointment times for med checks (15 min) allow high volume
• Good reimbursement with parity laws
• Low overhead compared to in-person practice
• Predictable revenue (monthly visits vs one-time therapy clients)

Regulatory Support

• Federal telehealth flexibilities continue through 2025 (likely beyond)
• State parity laws protect reimbursement
• Standard of care is well-established for telehealth ADHD management
• E-prescribing infrastructure is mature and widely adopted

Clinical Satisfaction

Many psychiatrists find ADHD medication management rewarding:

• Clear treatment protocols
• Measurable outcomes
• Helping patients who’ve struggled with focus/productivity
• Often younger, employed patients (less complex than severe mental illness)
• Lower risk than some other controlled substance prescribing (pain management)

Common Questions Psychiatrists Ask

Q: Can I prescribe Adderall on the first visit?

Yes, if you conduct a thorough evaluation and document appropriately. Under current federal flexibilities (through end of 2025), you don’t need an in-person visit first. However, some insurers or practice policies may require additional steps.

Q: What if federal telehealth rules expire?

Have a contingency: partner with local clinics for in-person exams, or work with platforms that facilitate hybrid care. Most experts expect extensions or permanent legislation, but prepare for potential changes.

Q: Do I need a special telehealth license?

No separate telehealth license exists, but you must be licensed in the state where the patient is located. Consider Interstate Medical Licensure Compact for easier multi-state practice.

Q: How do I handle PDMP requirements across multiple states?

Most telehealth platforms integrate PDMP access or provide support. Each state’s monitoring program has different interfaces but most allow provider registration. Budget 2-5 minutes per new prescription for PDMP checks.

Q: What about liability for prescribing controlled substances online?

Follow standard of care — thorough evaluation, ongoing monitoring, documentation of medical necessity. Your malpractice insurance should cover telehealth; confirm this. Practicing within scope and guidelines protects you legally.

Q: Can I do this part-time while maintaining my current practice?

Absolutely. Many psychiatrists start with 5-10 telehealth hours per week to test the model. Evenings and weekends work well for ADHD patients who are employed or in school.

The Platform Model: What to Look for in a Telehealth Partnership

If you’re considering joining a telehealth platform rather than building your own practice from scratch, evaluate these factors:

Patient Quality and Volume

• How are patients sourced and pre-qualified?
• What’s the typical time-to-first-appointment for new providers?
• Can you control your schedule and patient load?

Economic Model

• Pay-per-appointment vs salary vs percentage-based?
• Are you paying for marketing/patient acquisition or is it included?
• What’s your take-home after platform fees?
• Are there minimum volume requirements?

Infrastructure Support

• Is the telehealth platform HIPAA-compliant and reliable?
• E-prescribing built in or separate?
• Who handles billing/insurance credentialing?
• What administrative support is provided?

Clinical Autonomy

• Do you control treatment decisions or are there protocol restrictions?
• Can you decline to treat patients if clinically inappropriate?
• What’s the appeals process if there are patient complaints?

Legal/Compliance

• Does the platform support multi-state licensing?
• Who handles malpractice insurance (you or them)?
• Are PDMP checks integrated?
• What compliance training is provided?

For PMHNPs in Restricted States

• Does the platform provide collaborating physicians?
• How is supervision structured?
• Are there additional fees for collaboration arrangements?

Making the Decision: Is Telehealth ADHD Prescribing Right for You?

This practice model works well if you:

• Want to maximize clinical time (less commute, efficient scheduling)
• Are comfortable with technology (video platforms, e-prescribing, EHR systems)
• Prefer medication management over therapy (or want to focus on it)
• Want geographic flexibility (work from anywhere within licensed states)
• Value predictable schedules (you control appointment slots)
• Don’t want to deal with marketing (platforms handle patient acquisition)

It’s less ideal if you:

• Strongly prefer in-person interaction (though some providers adapt)
• Want to do primarily psychotherapy (though combined models exist)
• Are uncomfortable with controlled substance prescribing
• Need constant in-person team collaboration

Getting Started: Practical Next Steps

1. Verify your licensing

• Ensure your state medical/nursing license is current
• Check if you need additional state licenses for telehealth practice
• Confirm your DEA registration covers the states you’ll practice in

2. Get credentialed

• For insurance-based practice: start credentialing with major payers (90-120 days)
• For platform-based practice: platforms often handle this
• Update CAQH profile with telehealth capabilities

3. Set up technology

• HIPAA-compliant video platform (if not provided)
• E-prescribing system with DEA compliance (two-factor authentication)
• PDMP access in your state(s)
• Secure communication (encrypted email, patient portal)

4. Establish protocols

• Initial evaluation workflow
• Ongoing monitoring schedule
• Red flag criteria for controlled substance concerns
• Referral process for patients needing higher level of care

5. Consider joining a platform

• Compare economic models and support structures
• Evaluate patient volume and quality
• Understand technology and administrative support
• Review contract terms carefully (non-competes, patient ownership, exit terms)

The Bottom Line

Can psychiatrists prescribe ADHD medication via telehealth? Absolutely — and it’s one of the most in-demand, economically viable areas of telemedicine psychiatry in 2026.

The regulatory environment, while evolving, currently supports this practice through at least end of 2025. State-by-state variations matter significantly, especially for PMHNPs, but psychiatrists maintain full prescriptive authority everywhere.

The economics are compelling: strong demand, good reimbursement, low overhead, and efficient workflows. Patient acquisition is the traditional bottleneck, which is why platform models that handle marketing in exchange for per-appointment fees make economic sense for many providers — you’re paying for guaranteed results rather than gambling on uncertain marketing spend.

The clinical work itself — helping people with ADHD focus, function better, succeed at work and school — is genuinely rewarding. And you can do it from anywhere within your licensed states, on your schedule, without managing staff or office overhead.

If you’re a psychiatrist or experienced PMHNP looking to add telehealth ADHD care to your practice (or transition entirely), the infrastructure, demand, and economics are all aligned in 2026. The key is understanding the regulatory framework, choosing your practice model thoughtfully, and focusing on delivering high-quality care that meets — or exceeds — in-person standards.

Interested in joining a platform that handles patient acquisition while you focus on clinical care? Explore how Klarity connects psychiatrists and PMHNPs with pre-qualified ADHD patients, provides the technology infrastructure, and operates on a pay-per-appointment model that ensures you only pay when you see patients — no upfront marketing spend, no monthly fees, just guaranteed ROI for your time.

Sources and References

The following authoritative sources were used to compile this guide, with dates and reliability assessments:

Federal and State Legal Sources (High Reliability – Official Government Documents)

1. Florida Statutes §456.47 (Telehealth controlled substances exceptions) – Florida Legislature, Current through 2023 session, accessed February 2026. Authoritative legal text defining telehealth prescribing rules in Florida, specifically exceptions for psychiatric disorder treatment.

2. Florida Statutes §464.012 & §464.012(4) (APRN prescribing authority) – Florida Legislature, 2025 edition reflecting 2024 laws. Direct legislative source detailing NP scope, 7-day Schedule II limit, and psychiatric nurse exception.

3. Texas SB 2527 Bill Analysis (88th Legislature) – Texas State Legislature, April 2023. Government document providing legislative analysis of telehealth controlled substance prescribing concerns in Texas.

4. Pennsylvania Code – 49 Pa. Code §21.284 (CRNP prescribing parameters) – Pennsylvania Code and Bulletin, Current through 2021 amendments. Primary source for PA NP prescribing limits (72-hour initial, 30-day ongoing for Schedule II).

5. Illinois Nurse Practice Act – 225 ILCS 65 (APRN Full Practice Authority) – Illinois General Assembly, Amended 2017, effective 2018. Authoritative details on NP FPA requirements including 4,000-hour experience threshold.

Healthcare Policy and News Sources (High Reliability – Major News Organizations)

6. Axios – ‘COVID-era telehealth prescribing extended again’ (November 18, 2024). Credible healthcare policy journalism confirming DEA extension of controlled substance telehealth flexibilities through December 31, 2025.

7. Axios – ‘Telehealth prescribing mess could reach Congress’ (September 18, 2024). Policy analysis on impending expiration concerns and federal agency positions on telehealth prescribing.

8. Associated Press – ‘More adults sought help for ADHD during pandemic…’ (January 10, 2024). Reputable newswire citing JAMA Psychiatry study on ADHD prescription surge and shortage context.

Professional and Industry Sources (Medium-High Reliability – Well-Referenced Professional Resources)

9. RxAgent – ‘NP Prescriptive Authority by State (2026 Guide)’ (Updated December 28, 2025). Comprehensive PharmD-authored state-by-state summary of NP scope and controlled substance laws, well-referenced with AANP citations.

10. Center for Connected Health Policy (CCHP) – ‘Texas State Telehealth Laws’ (Last updated January 19, 2026). Comprehensive, regularly updated summary of state telehealth laws by respected non-profit specializing in telehealth policy.

11. Therathink – ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ (Updated 2026). Practice management resource providing detailed CPT code reimbursement figures derived from CMS data for Medicare, Medicaid, and commercial payers.

12. BehaveHealth – ‘Mental Health Reimbursement Trends – Telehealth Parity 2026’ (2024). Industry analysis on telehealth payment parity status across states.

13. Healing Psychiatry Florida – ‘Psychiatrist Shortage by State – 2026 Report’ (January 15, 2026). Data compilation on psychiatrist-to-population ratios by state, likely sourced from HRSA data.

All sources accessed and verified February 2026. Official statutes and regulations reflect the most current available information as of 2025-2026. Regulatory statements have been cross-verified against multiple sources where possible. Dynamic policy areas (such as federal telehealth extensions) are clearly noted with timeline context and uncertainty acknowledgments.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the